As attorneys who have concentrated for several decades on helping clients with long-term chronic disabilities, we have witnessed the hardships that people with disabilities and their families face on a daily basis.
Many of the services deployed to treat people addressed the delivery of quality care (in a home or facility setting) and financing the cost over a lifetime after diagnosis and through the slow progression of the disease.
Preventing or mitigating the effects of such diseases has always been in the background. Fortunately, promising new research points toward identifying the signs of diseases such as Alzheimer’s and Parkinson’s before actual onset, which allows physicians to offer early therapeutic treatment.
A recent study by Dr. Pravat Mandal of the National Brain Research Institute of India, with Dr. Joseph Maroon, a neurosurgeon, clinical professor and Heindl Scholar in Neuroscience at the University of Pittsburgh, found the following:
Using state-of-the-art magnetic resonance spectroscopy, the team measured the chemical composition of the brain noninvasively. They discovered that in normal patients at all ages, brain and blood glutathione levels and metallic profiles are maintained in a balanced state.
They also reviewed their earlier study in which they documented lower blood GSH and increased iron levels in the brain in patients with mild cognitive impairment and with confirmed Alzheimer’s. They believe deficient GSH, the main antioxidant in the brain, is a major contributing cause of subsequent neurodegeneration in Alzheimer’s, Parkinson’s and traumatic brain injury.
Read More
Based on their studies, MR spectroscopy appears to offer a non-invasive neuroimaging biomarker to diagnose AD and PD. Their recently published study and associated analysis from the scientific literature indicates that a low GSH (in plasma) and decreased iron level in the blood (serum) may also be potential biomarkers and indicate a significant risk factor for AD.
Two clinical trials are listed in the clinicaltrials.gov portal (PD trial and repetitive head impact trial)
Importantly, with a grant from the Chuck Noll Foundation, they will attempt to raise GSH levels by giving Glyteine, a GSH precursor, to a group of former NFL players, Navy Seals and combat soldiers exposed to repetitive trauma to the brain.
While these findings will need further validation, this is a significant leap forward as prior confirmation of AD of deficient GSH in AD was only found via a postmortem examination of the patient’s brain.
On the therapeutic side, hyperbaric oxygen therapy shows promise for treating a wide variety of brain injuries. HBOT enhances oxygen delivery, neuroplasticity and brain cell regeneration by exposing the entire body to increased atmospheric pressure while breathing 100% oxygen. It is already being used for helping veterans with Post Traumatic Stress Disorder, TBI and post-concussion syndrome. Ongoing studies are investigating HBOT for the adjunctive treatment of AD, PD and Autism Spectrum Disorders.
Dr. Maroon has published and lectured extensively on the use of HBOT for healing the brain, increasing recovery and enhancing athletic performance. He also has witnessed striking results in patients with long COVID, post-concussion syndrome and post stoke.
As with any emerging treatment, insurance coverage is the key to widespread adoption.
According to the Centers for Medicare and Medicaid Services, Medicare will pay for healing wounds of extremities, but does not currently cover HBOT for wounds of the brain discussed in this column. For a list of current Medicare approved conditions for HBOT visit: www.medicare.gov/coverage/hyperbaric-oxygen-therapy. Twelve states now pay for HBOT treatment of veterans with PTSD. In addition, there are other ongoing studies specifically targeting TBI and PD. Results thus far have been mixed and larger studies are needed.
In summary, while we, as a society, continue to address the ongoing caregiving and financing needs for individuals with these types of injuries and chronic diseases, there is promising research that has taken the notion of early identification and therapy to a new level not seen in years.
Julian Gray and Frank Petrich are both Certified Elder Law Attorneys with over 70 years of combined elder law experience who practice in the Pittsburgh area at Julian Gray Associates. Send questions for consideration in this column to elderlawguys@grayelderlaw.com and visit their web site at www.grayelderlaw.com.



Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.